Henry Schein (HSIC) is back in focus after recent share price moves, with the stock last closing at US$88.50. Investors are assessing how the current valuation lines up with the company’s fundamentals and recent performance.

Recent moves have come after a solid run, with Henry Schein’s 90 day share price return of 19.26% and year to date share price return of 15.20%, alongside a 1 year total shareholder return of 27.16%.

If you are assessing Henry Schein and want more context, it can help to compare it with other healthcare related opportunities through 41 healthcare AI stocks

After that kind of run, the question is whether Henry Schein’s current price still offers a comfortable trade off between risk and potential reward. The next step is to see what the valuation says.

Most Popular Narrative: 9.3% Undervalued

Henry Schein’s most followed narrative points to a fair value of $97.56 compared with the last close at $88.50, framing the stock as modestly undervalued on these assumptions.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.

Want to see what is baked into that $97.56 fair value for Henry Schein? The narrative leans heavily on earnings growth, margin uplift, and a future P/E reset.

The narrative uses a discount rate of 7.36% and ties its fair value to assumptions about mid single digit revenue growth, gradual margin improvement, and a lower P/E multiple than today. Analysts also factor in lower share count over time, which supports earnings per share in their model even with moderate top line growth.

Result: Fair Value of $97.56 (UNDERVALUED)

However, Henry Schein’s story still hinges on execution, with competitive pricing pressure in key products and ongoing staffing shortages in dental practices both capable of undermining that valuation narrative.

Next Steps

Given the mix of optimism and concern around Henry Schein, it makes sense to check the details yourself and move quickly to form your own view. To help balance the positives against the potential downsides, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Henry Schein?

If Henry Schein has sharpened your focus, do not stop here. Broaden your watchlist now so you are not chasing opportunities after they have already moved.

• Target potential mispricings by scanning companies that combine quality with attractive entry points through the 48 high quality undervalued stocks.
• Strengthen your income ideas by reviewing companies with robust payouts using the 12 dividend fortresses.
• Prioritise resilience first and search for companies with steadier profiles using the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.